iRadimed Sees Q4 Adj EPS $0.47-$0.51 vs $0.47 Est; Sees Sales $21.400M-$22.400M vs $20.733M Est
Benzinga Newsdesk 1 year ago
NewsGuidance
iRadimed (NASDAQ:IRMD) is looking for Q4 Adj EPS of $0.47-$0.51 vs $0.47 analyst estimate. sees sales of $21.400 million-$22.400 million vs $20.733 million analyst estimate.
iRadimed (NASDAQ:IRMD) is looking for Q4 Adj EPS of $0.47-$0.51 vs $0.47 analyst estimate. sees sales of $21.400 million-$22.400 million vs $20.733 million analyst estimate.